Betta Pharmaceuticals Co. Ltd. (300558)

Overview

Betta Pharmaceuticals Co., Ltd. is a recognized entity in the pharmaceutical industry of China, dedicated to the advancement, production, and distribution of medications aimed at combating cancer. Founded in the year 2003, the company has established its headquarters in Hangzhou, China. Leveraging cutting-edge research and development strategies, Betta Pharmaceuticals has carved a niche for itself by focusing on innovative treatments for non-small-cell lung cancer, among other cancer types.

Products and Services

• Icotinib Hydrochloride

This product stands as an oral epidermal growth factor receptor tyrosine kinase inhibitor, crafted explicitly for the treatment of non-small-cell lung cancer. By targeting and inhibiting specific tyrosine kinases associated with cancer cell growth and survival, Icotinib hydrochloride offers a targeted therapy approach, providing a beacon of hope for patients battling this form of lung cancer.

• Ensartinib Hydrochloride

Another innovative product in Betta Pharmaceuticals' arsenal, Ensartinib hydrochloride, functions as an anaplastic lymphoma kinase inhibitor. It is also geared towards the treatment of non-small cell lung cancer, with a specific focus on inhibiting the anaplastic lymphoma kinase pathway. This action disrupts the cancer cells' growth and proliferation, thereby offering a potent option for managing this disease.